JERUSALEM, March 5, 2015 /PRNewswire/ -- BioLineRx (NASDAQ:
BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company
dedicated to identifying, in-licensing and developing promising
therapeutic candidates, today announced that it has commenced an
underwritten public offering of American Depositary Shares
("ADSs"), each representing ten (10) of its Ordinary Shares. All of
the ADSs in the offering are to be sold by BioLineRx.
JMP Securities is acting as sole book-running manager for the
offering. BioLineRx intends to grant the underwriters a
30-day option to purchase up to an additional 15 percent of the
amount sold to cover over-allotments, if any. The offering is
subject to market conditions, and there can be no assurance as to
whether or when the offering may be completed, or as to the actual
size or terms of the offering.
The ADSs will be issued pursuant to a shelf registration
statement that was previously filed with, and declared effective
by, the Securities and Exchange Commission (SEC). A final
prospectus supplement related to the offering will be filed with
the SEC and will be available on the SEC's website located at
www.sec.gov.
This press release does not constitute an offer to sell or a
solicitation of an offer to buy nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction. Any offer, if at all, will be made only by means of a
prospectus supplement and accompanying prospectus forming a part of
the effective registration statement, copies of which may be
obtained, when available, from JMP Securities LLC, 600 Montgomery
Street, 10th Floor, San Francisco,
California 94111, Attention: Prospectus Department, or by
telephone: (415) 835-8985.
About BioLineRx
BioLineRx is a publicly-traded, clinical-stage biopharmaceutical
company dedicated to identifying, in-licensing and developing
promising therapeutic candidates. The Company in-licenses novel
compounds primarily from academic institutions and biotech
companies based in Israel,
develops them through pre-clinical and/or clinical stages, and then
partners with pharmaceutical companies for advanced clinical
development and/or commercialization.
BioLineRx's current portfolio consists of a variety of clinical
and pre-clinical projects, including: BL-1040 for prevention of
pathological cardiac remodeling following a myocardial infarction,
which has been out-licensed to Bellerophon BCM (f/k/a Ikaria) and
is in the midst of a pivotal CE-Mark registration trial scheduled
for completion in mid-2015; BL-8040, a cancer therapy platform,
which is in the midst of a Phase 2 study for acute myeloid leukemia
(AML) as well as a Phase 1 study for stem cell mobilization; and
BL-7010 for celiac disease, which has successfully completed a
Phase 1/2 study.
In December 2014, BioLineRx
entered into a strategic collaboration with Novartis for the
co-development of selected Israeli-sourced novel drug candidates.
The companies intend to co-develop a number of pre-clinical and
early clinical therapeutic projects through clinical
proof-of-concept for potential future licensing by Novartis.
For more information on BioLineRx, please visit
www.biolinerx.com or download the investor relations mobile device
app, which allows users access to the Company's SEC documents,
press releases, and events. BioLineRx's IR app is available on the
iTunes App Store as well as the
Google Play Store.
Various statements in this release concerning BioLineRx's
future expectations constitute "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995. These statements include words such as "may," "expects,"
"anticipates," "believes," and "intends," and describe opinions
about future events. These forward-looking statements involve known
and unknown risks and uncertainties that may cause the actual
results, performance or achievements of BioLineRx to be materially
different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Some of
these risks are: changes in relationships with collaborators; the
impact of competitive products and technological changes; risks
relating to the development of new products; and the ability to
implement technological improvements. These and other factors are
more fully discussed in the "Risk Factors" section of BioLineRx's
most recent annual report on Form 20-F filed with the Securities
and Exchange Commission on March 17,
2014. In addition, any forward-looking statements represent
BioLineRx's views only as of the date of this release and should
not be relied upon as representing its views as of any subsequent
date. BioLineRx does not assume any obligation to update any
forward-looking statements unless required by law.
Contact:
Tiberend Strategic Advisors, Inc.
Joshua Drumm, Ph.D.
jdrumm@tiberend.com
+1-212-375-2664
Andrew Mielach
amielach@tiberend.com
+1-212-375-2694
or
Tsipi Haitovsky
Public Relations
+972-3-6240871
tsipihai5@gmail.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/biolinerx-announces-underwritten-public-offering-of-its-american-depositary-shares-300046425.html
SOURCE BioLineRx